Axio BioPharma
Axio BioPharma is revolutionizing biopharma manufacturing with AI-driven platform and services. Their mission is to accelerate monoclonal antibody development, reduce costs, and improve quality through innovative AI solutions. They offer a range of services including process development, discovery manufacturing, research-grade manufacturing, and GMP manufacturing, supporting biopharma companies from discovery to commercialization. The company also develops proprietary antibodies like MKLP1 Pro™ for cancer diagnostics and research, and actively engages in industry news and partnerships to advance biologics development.
Industries
Nr. of Employees
small (1-50)
Products
MKLP1 Pro IgG
Full-length MKLP1-targeting IgG antibody designed for broad epitope coverage and cross-species detection; recommended for immunofluorescence and localization assays and compatible with flow cytometry, Western blot, and standard IP protocols.
MKLP1 Pro IgM
Full-length MKLP1-targeting IgM antibody formatted as a pentamer to provide high avidity and effective antigen precipitation; intended for immunoprecipitation and applications requiring high-affinity capture.
MKLP1 Pro IgG
Full-length MKLP1-targeting IgG antibody designed for broad epitope coverage and cross-species detection; recommended for immunofluorescence and localization assays and compatible with flow cytometry, Western blot, and standard IP protocols.
MKLP1 Pro IgM
Full-length MKLP1-targeting IgM antibody formatted as a pentamer to provide high avidity and effective antigen precipitation; intended for immunoprecipitation and applications requiring high-affinity capture.
Services
Design and optimization of manufacturing strategies for mammalian-expressed proteins to create robust, scalable processes suitable for scale-up.
Small-scale parallel manufacturing services for early-stage discovery (96-well plate workflows up to 2 L shake-flask expression) to accelerate screening and lead selection.
Provision of consistent research-grade protein production to support R&D and preclinical studies with reproducible results.
GMP manufacturing services delivered via strategic partners, including large-scale production and support for clinical development activities.
Design and optimization of manufacturing strategies for mammalian-expressed proteins to create robust, scalable processes suitable for scale-up.
Small-scale parallel manufacturing services for early-stage discovery (96-well plate workflows up to 2 L shake-flask expression) to accelerate screening and lead selection.
Provision of consistent research-grade protein production to support R&D and preclinical studies with reproducible results.
GMP manufacturing services delivered via strategic partners, including large-scale production and support for clinical development activities.
Expertise Areas
- Monoclonal antibody development
- AI-driven bioprocess modeling
- Process development for mammalian-expressed proteins
- Small-scale discovery manufacturing
Key Technologies
- Machine learning for protein and process prediction
- Sequence-based feature engineering
- In silico process simulation and DoE
- Predictive process modeling
News & Updates
Axio BioPharma, based in Madison, Wisconsin, has initiated services for recombinant protein manufacturing, including monoclonal antibody production. Operating from Forward BIOLABS, the company aims to support biologics development by offering high-quality protein production capabilities.
Forward BIOLABS, with backing from the Wisconsin Economic Development Corporation, has selected 15 early-stage biohealth companies for its 2024 Forward Membership Program. The program provides access to fully equipped co-working labs, resources, and a supportive community to accelerate innovation. Notably, 74% of the selected startups are led by women or minorities, emphasizing the program's commitment to diversity.
eMBR Genomics has partnered with Axio BioPharma to manufacture and distribute MKLP1 Pro™ antibodies, targeting advancements in cancer diagnostics. The antibodies, available in IgM and IgG formats, are designed to facilitate research into midbody remnants and large extracellular vesicles, potentially leading to non-invasive early cancer detection methods.
In a WisBusiness podcast episode, Justin Byers, CEO of Axio BioPharma, elaborates on the company's use of AI to streamline protein manufacturing processes. By integrating AI into process development, Axio aims to reduce time and costs for clients. The company plans to expand its production capacity and workforce in Madison, Wisconsin.
Axio BioPharma, based in Madison, Wisconsin, has initiated services for recombinant protein manufacturing, including monoclonal antibody production. Operating from Forward BIOLABS, the company aims to support biologics development by offering high-quality protein production capabilities.
Forward BIOLABS, with backing from the Wisconsin Economic Development Corporation, has selected 15 early-stage biohealth companies for its 2024 Forward Membership Program. The program provides access to fully equipped co-working labs, resources, and a supportive community to accelerate innovation. Notably, 74% of the selected startups are led by women or minorities, emphasizing the program's commitment to diversity.
eMBR Genomics has partnered with Axio BioPharma to manufacture and distribute MKLP1 Pro™ antibodies, targeting advancements in cancer diagnostics. The antibodies, available in IgM and IgG formats, are designed to facilitate research into midbody remnants and large extracellular vesicles, potentially leading to non-invasive early cancer detection methods.
In a WisBusiness podcast episode, Justin Byers, CEO of Axio BioPharma, elaborates on the company's use of AI to streamline protein manufacturing processes. By integrating AI into process development, Axio aims to reduce time and costs for clients. The company plans to expand its production capacity and workforce in Madison, Wisconsin.